SCHEMBL3090430

SCHEMBL3090430

CCN(C(=O)C(Cc1cnn(Cc2ccc(Cl)nc2)c1)C(=O)NS(=O)(=O)/C=C/c1ccccc1)c1ccc(F)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.36
HDAC2 Q92769 2/20 0.34
TCF4 P15884 1/20 0.33
CTNNB1 P35222 1/20 0.33
HDAC3 O15379 1/20 0.33
JAK2 O60674 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC11 Q96DB2 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
HDAC9 Q9UKV0 1/20 0.33
HDAC5 Q9UQL6 1/20 0.33
NFE2L2 Q16236 1/20 0.31
GBA1 P04062 1/20 0.31
MAPT P10636 4/20 0.31
ALDH1A1 P00352 4/20 0.31
KDM4E B2RXH2 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3090431 1.00 LMNA (0.36) LMNAHDAC2TCF4CTNNB1HDAC3
SCHEMBL3085954 0.95 GAA (0.32) LMNAHDAC8HDAC6NFE2L2MAPT
SCHEMBL3085957 0.95 GAA (0.32) LMNAHDAC8HDAC6NFE2L2MAPT
SCHEMBL3097471 0.93 LMNA (0.40) LMNAHDAC2TCF4CTNNB1HDAC3
SCHEMBL3097463 0.93 LMNA (0.40) LMNAHDAC2TCF4CTNNB1HDAC3
SCHEMBL3078964 0.93 LMNA (0.39) LMNAHDAC2TCF4CTNNB1GBA1
SCHEMBL3078960 0.93 LMNA (0.39) LMNAHDAC2TCF4CTNNB1GBA1
SCHEMBL3090762 0.90 LMNA (0.39) LMNAHDAC2TCF4CTNNB1HDAC3
SCHEMBL3090767 0.90 LMNA (0.39) LMNAHDAC2TCF4CTNNB1HDAC3
SCHEMBL3469656 0.89 F2 (0.35) LMNAHDAC2HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 LMNA 3803/4885HDAC2 1497/4885TCF4 4135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.